Phase 2 N=22 Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain
Fibromyalgia
Primary: Widespread Pain Index (WPI) Score After 4 Weeks Treatment — 13.0; 8.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=61 Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Ovarian Neoplasms
Primary: Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST…
Phase 2 N=168 Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12) — 84.9; 69.6; 74.5; 95 Percentage of participants
Phase 2 N=24 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Kidney Cancer
Primary: Overall Objective Response Rate as Measured by RECIST — 1; 16; 6 participants
Phase 2 N=92 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Carcinoma · Renal Cell · Non Clear Cell Renal Carcinoma
Primary: To Evaluate Efficacy of RAD001 as Monotherapy for the Treatment of Papillary Renal Cancer. Efficacy is Defined as the Percentage of Patients Progression-free at 6…
Phase 2 N=110 A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24) — 100; 88.9; 100; 100 percentage of participants
Phase 2 N=30 Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant
Failure of Bone Marrow Graft
Primary: Time to Neutrophil Recovery — 17 days
Phase 2 N=55 A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Melanoma
Primary: Overall Response Rate (ORR) — 11; 3 Participants
Phase 2 N=341 Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
Influenza
Primary: The Difference in Seroconversion/Immunogenicity Between rHA Formulated in an oil-in- Water Adjuvant (SE) Compared to a rHA Antigen Alone. — 83; 70; 9; 76 percentage of…
Phase 2 N=27 Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
Stroke · Brain Infarction
Primary: The Number of Patients Who Experience Symptomatic Intracerebral Hemorrhage (sICH). — 1 participants
Phase 2 N=16 Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Esophageal Cancer · Gastric Cancer
Primary: Complete and Partial Response Rate — 0; 1; 4; 11 participants
Phase 2 N=22 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Brain and Central Nervous System Tumors · Childhood Germ Cell Tumor · Extragonadal Germ Cell Tumor
Primary: Response Rate After Every 3 Courses During Treatment and Then Every 2-3 Months for 1 Year After Completion of Treatment — 16; 5 participants
Phase 2 N=10 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Phase 2 N=471 Tofacitinib Ointment For Chronic Plaque Psoriasis
Psoriasis Vulgaris · Psoriasis
Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…
Phase 2 N=12 Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days